Analysts expect a surge in US-China biotech deals as US restrictions appear less likely
According to SCMP Business, US-China biotech deals are expected to thrive as Washington is reportedly leaning away from sweeping restrictions, boosting Chinese healthcare firms under Beijing’s five-year plan. Nomura’s head of China healthcare research Jialin Zhang said out-licensing deals between China and the US would ride on a high tide in the favourable environment, the report notes, while the US Treasury Department was drafting investment measures.
Key facts
- 01Nomura’s Jialin Zhang is identified as the head of China healthcare research.
- 02Out-licensing deals between China and the US are anticipated to increase.
- 03Beijing’s five-year plan for the biotech sector is referenced as context for optimism.
- 04The US Treasury Department was drafting investment measures.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.